Navigation Links
Slow federal action to oversee nanotechnology leaves 'room at the bottom'
Date:4/9/2008

Washington, DC State and local governments often have adopted trailblazing initiatives to address environmental, health and safety concerns in advance or in lieu of federal action. With nanotechnology, an emerging field of science with unknown risks, this practice is continuing, a landmark study has found.

In the absence of action at the federal level, local and state governments may begin to explore their options for oversight of nanotechnology, says Suellen Keiner, author of the new Project on Emerging Nanotechnologies (PEN) report, Room at the Bottom" Potential State and Local Strategies for Managing the Risks and Benefits of Nanotechnology. Keiner is the Chief Operating Officer of State of the USA, Inc., a new non-profit organization that is building a system of key indicators to measure economic, environmental and social conditions across the nation.

In regard to oversight of nanotechnology, Berkeley, CA, has taken the lead by adopting an ordinance that requires handlers of nanomaterials to submit toxicology reports on the materials to the city. Elected officials in Cambridge, MA, and Madison, WI, have also begun to look at similar reporting mechanisms. However, the prospect of a patchwork of state and local regulations is cause for concern among policy experts.

The scenario of having a number of different local regulations is not ideal, but it could serve as a catalyst to force the federal government or Congress whether through administrative regulation or legislation to address the potential negative impacts of engineered nanomaterials, says David Rejeski, the director of PEN.

The report discusses possible options for state and local governments to follow that would allow for oversight of the potential negative impacts of nanotechnology including local air, waste and water regulations, as well as labeling and worker safety requirements.


'/>"/>

Contact: Colin Finan
colin.finan@wilsoncenter.org
202-691-4321
Project on Emerging Nanotechnologies
Source:Eurekalert

Page: 1

Related biology technology :

1. Hepatitis B Foundation Testifies Before Congressional Appropriation Committee and Urges More Federal Funding for Hepatitis B
2. Federal nanotech risk research plan still comes up short
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
5. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
6. Zimmer Announces Settlement of Federal Investigation
7. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
8. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. Martek Announces Final Judgment and Order of Dismissal in Class Action
11. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2Single Moms Clever Idea 3A Kill Head Lice With Salt 56133 1Single Moms Clever Idea 3A Kill Head Lice With Salt 56133 2Single Moms Clever Idea 3A Kill Head Lice With Salt 56133 3Encap agrees colonic drug delivery licensing deal 9775 1Encap agrees colonic drug delivery licensing deal 9775 2Encap agrees colonic drug delivery licensing deal 9775 3PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 1PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 2PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 3PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 4PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 5PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 6PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 7PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 8PharmAthene Presents Data for Valortim 28R 29 Anthrax Anti Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus ACT 2009 Conferen 13827 9